Oncology Meets Immunology: The Cancer-Immunity Cycle

Boon, 1994, Tumor antigens recognized by T lymphocytes, Annu. Rev. Immunol., 12, 337, 10.1146/annurev.iy.12.040194.002005

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609

Brahmer, 2013, Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC), J. Clin. Oncol., 31, 8030, 10.1200/jco.2013.31.15_suppl.8030

Brestoff, 2013, Commensal bacteria at the interface of host metabolism and the immune system, Nat. Immunol., 14, 676, 10.1038/ni.2640

Bulgaru, 2003, Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase, Expert Rev. Anticancer Ther., 3, 269, 10.1586/14737140.3.3.269

Chemnitz, 2004, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J. Immunol., 173, 945, 10.4049/jimmunol.173.2.945

Chen, 2012, Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1, Clin. Cancer Res., 18, 6580, 10.1158/1078-0432.CCR-12-1362

Cho, 2013, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC), J. Clin. Oncol., 31, 4505, 10.1200/jco.2013.31.15_suppl.4505

Corbière, 2011, Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases, Cancer Res., 71, 1253, 10.1158/0008-5472.CAN-10-2693

Davis, 2012, Immunology taught by humans, Sci. Transl. Med., 4, 117fs2, 10.1126/scitranslmed.3003385

Demaria, 2005, Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer, Clin. Cancer Res., 11, 728, 10.1158/1078-0432.728.11.2

Drake, 2013, Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up, J. Clin. Oncol., 31, 4514, 10.1200/jco.2013.31.15_suppl.4514

Dunn, 2002, Cancer immunoediting: from immunosurveillance to tumor escape, Nat. Immunol., 3, 991, 10.1038/ni1102-991

Duraiswamy, 2013, Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors, Cancer Res., 73, 3591, 10.1158/0008-5472.CAN-12-4100

Ferguson, 2011, Armed response: how dying cells influence T-cell functions, Immunol. Rev., 241, 77, 10.1111/j.1600-065X.2011.01006.x

Francisco, 2010, The PD-1 pathway in tolerance and autoimmunity, Immunol. Rev., 236, 219, 10.1111/j.1600-065X.2010.00923.x

Franciszkiewicz, 2012, Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response, Cancer Res., 72, 6325, 10.1158/0008-5472.CAN-12-2027

Franciszkiewicz, 2013, CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions, Cancer Res., 73, 617, 10.1158/0008-5472.CAN-12-2569

Gajewski, 2012, Cancer immunotherapy, Mol. Oncol., 6, 242, 10.1016/j.molonc.2012.01.002

Gajewski, 2011, Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment, Curr. Opin. Immunol., 23, 286, 10.1016/j.coi.2010.11.013

Gajewski, 2013, Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment, Curr. Opin. Immunol., 25, 268, 10.1016/j.coi.2013.02.009

Galon, 2013, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, 39, 11, 10.1016/j.immuni.2013.07.008

Ge, 2013, Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice, Cancer Lett., 336, 253, 10.1016/j.canlet.2013.03.010

Goding, 2013, Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma, J. Immunol., 190, 4899, 10.4049/jimmunol.1300271

Greaves, 2013, The role of B7 family molecules in hematologic malignancy, Blood, 121, 734, 10.1182/blood-2012-10-385591

Grosso, 2013, Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538), J. Clin. Oncol., 31, 3016, 10.1200/jco.2013.31.15_suppl.3016

Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 10.1056/NEJMoa1305133

Hamid, 2013, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM), J. Clin. Oncol., 31, 9010, 10.1200/jco.2013.31.15_suppl.9010

Heo, 2013, Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer, Nat. Med., 19, 329, 10.1038/nm.3089

Herbst, 2013, A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors, J. Clin. Oncol., 31, 3000, 10.1200/jco.2013.31.15_suppl.3000

Hiniker, 2012, A systemic complete response of metastatic melanoma to local radiation and immunotherapy, Transl Oncol, 5, 404, 10.1593/tlo.12280

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N. Engl. J. Med., 363, 711, 10.1056/NEJMoa1003466

Huang, 2013, B-Raf and the inhibitors: from bench to bedside, J Hematol Oncol, 6, 30, 10.1186/1756-8722-6-30

Isaacs, 1996, A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans, Clin. Exp. Immunol., 106, 427, 10.1046/j.1365-2249.1996.d01-876.x

Jacobs, 2012, Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?, Lancet Oncol., 13, e32, 10.1016/S1470-2045(11)70155-3

James, 2012, Diet-induced obesity alters dendritic cell function in the presence and absence of tumor growth, J. Immunol., 189, 1311, 10.4049/jimmunol.1100587

Kalos, 2013, Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, 39, 49, 10.1016/j.immuni.2013.07.002

Karan, 2012, Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity, Immunotherapy, 4, 577, 10.2217/imt.12.53

Kasuga, 2013, Comprehensive analysis of MHC ligands in clinical material by immunoaffinity-mass spectrometry, Methods Mol. Biol., 1023, 203, 10.1007/978-1-4614-7209-4_14

Kochenderfer, 2013, Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors, Nat Rev Clin Oncol, 10, 267, 10.1038/nrclinonc.2013.46

Kruit, 2013, Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in metastatic melanoma, J. Clin. Oncol., 31, 2413, 10.1200/JCO.2012.43.7111

Lin, 2013, Explaining why Gleevec is a specific and potent inhibitor of Abl kinase, Proc. Natl. Acad. Sci. USA, 110, 1664, 10.1073/pnas.1214330110

Lippitz, 2013, Cytokine patterns in patients with cancer: a systematic review, Lancet Oncol., 14, e218, 10.1016/S1470-2045(12)70582-X

Liu, 2013, BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice, Clin. Cancer Res., 19, 393, 10.1158/1078-0432.CCR-12-1626

Madan, 2012, Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial, Lancet Oncol., 13, 501, 10.1016/S1470-2045(12)70006-2

Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673

Motz, 2013, Deciphering and Reversing Tumor Immune Suppression, Immunity, 39, 61, 10.1016/j.immuni.2013.07.005

Mullard, 2013, New checkpoint inhibitors ride the immunotherapy tsunami, Nat. Rev. Drug Discov., 12, 489, 10.1038/nrd4066

Ott, 2013, Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties, Cancer Immunol. Immunother., 62, 811, 10.1007/s00262-012-1389-z

Palucka, 2013, Dendritic-cell-based therapeutic cancer vaccines, Immunity, 39, 38, 10.1016/j.immuni.2013.07.004

Parry, 2005, CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms, Mol. Cell. Biol., 25, 9543, 10.1128/MCB.25.21.9543-9553.2005

Patnaik, 2012, Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors, J. Clin. Oncol., 30, 2512, 10.1200/jco.2012.30.15_suppl.2512

Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res., 72, 5209, 10.1158/0008-5472.CAN-12-1187

Postow, 2012, Immunologic correlates of the abscopal effect in a patient with melanoma, N. Engl. J. Med., 366, 925, 10.1056/NEJMoa1112824

Powderly, 2013, Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study, J. Clin. Oncol., 31, 3001, 10.1200/jco.2013.31.15_suppl.3001

Predina, 2013, Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery, Proc. Natl. Acad. Sci. USA, 110, E415, 10.1073/pnas.1211850110

Qureshi, 2011, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, 332, 600, 10.1126/science.1202947

Rammensee, 2002, Towards patient-specific tumor antigen selection for vaccination, Immunol. Rev., 188, 164, 10.1034/j.1600-065X.2002.18815.x

Riella, 2012, Role of the PD-1 pathway in the immune response, Am. J. Transplant., 12, 2575, 10.1111/j.1600-6143.2012.04224.x

Rotem-Yehudar, 2009, CT-011, a humanized monoclonal antibody, interacts with the PD-1 receptor and modulates survival and trafficking signals in effector/memory T lymphocytes, Proc. Am. Assoc. Cancer Res.

Rothman, 2013, Live-attenuated Listeria-based immunotherapy, Expert Rev. Vaccines, 12, 493, 10.1586/erv.13.34

Rothschild, 2013, Crizotinib in the Treatment of Non-Small-Cell Lung Cancer, Clin. Lung Cancer, 10.1016/j.cllc.2013.04.006

Segal, 2008, Epitope landscape in breast and colorectal cancer, Cancer Res., 68, 889, 10.1158/0008-5472.CAN-07-3095

Smothers, 2013, AMP-224, A fusion Protein That Targets PD-1, Ann. Oncol., 24, i7, 10.1093/annonc/mdt042.6

So, 2006, Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity, Int. J. Hematol., 83, 1, 10.1532/IJH97.05120

Spigel, 2013, Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), J. Clin. Oncol., 31, 8008, 10.1200/jco.2013.31.15_suppl.8008

Stagg, 2011, Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy, Proc. Natl. Acad. Sci. USA, 108, 7142, 10.1073/pnas.1016569108

Stewart, 2011, Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development, Cancer Res., 71, LB-158, 10.1158/1538-7445.AM2011-LB-158

Sznol, 2013, Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538), J. Clin. Oncol., 31, CRA9006, 10.1200/jco.2013.31.18_suppl.cra9006

Tabernero, 2013, Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors, J. Clin. Oncol., 31, 3622, 10.1200/jco.2013.31.15_suppl.3622

Tian, 2011, The origins of cancer robustness and evolvability, Integr Biol (Camb), 3, 17, 10.1039/C0IB00046A

Topalian, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Curr. Opin. Immunol., 24, 207, 10.1016/j.coi.2011.12.009

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690

Topalian, 2013, Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial, J. Clin. Oncol., 31, 3002, 10.1200/jco.2013.31.15_suppl.3002

van den Boorn, 2013, Turning tumors into vaccines: Co-opting the Innate Immune System, Immunity, 39, 27, 10.1016/j.immuni.2013.07.011

Vanneman, 2012, Combining immunotherapy and targeted therapies in cancer treatment, Nat. Rev. Cancer, 12, 237, 10.1038/nrc3237

Vansteenkiste, 2013, Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: Phase II randomized study results, J. Clin. Oncol., 31, 2396, 10.1200/JCO.2012.43.7103

Wang, 2013, Immune evasion evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells, Haematologica, 10.3324/haematol.2012.071340

West, 2013, PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells, J. Clin. Invest., 123, 2604, 10.1172/JCI67008

Westin, 2012, Phase II Safety and Efficacy Study of CT-011, a Humanized anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma, Blood, 120, 793, 10.1182/blood.V120.21.793.793

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med., 10.1056/NEJMoa1302369

Xu, 2012, mTOR, linking metabolism and immunity, Semin. Immunol., 24, 429, 10.1016/j.smim.2012.12.005

Zitvogel, 2013, Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance, Immunity, 39, 74, 10.1016/j.immuni.2013.06.014